<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01705002</url>
  </required_header>
  <id_info>
    <org_study_id>PROMITIL-01</org_study_id>
    <nct_id>NCT01705002</nct_id>
  </id_info>
  <brief_title>Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PROMITIL) in Cancer Patients With Solid Tumors.</brief_title>
  <official_title>A Phase I, Dose-Escalating, Safety Study of an Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PL-MLP, PROMITIL) in Cancer Patients With Solid Tumors.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lipomedix Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lipomedix Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I, multi-center, Dose-Escalating, Safety Study of an Intravenously&#xD;
      Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PL-MLP, PROMITIL) in Cancer&#xD;
      Patients with Solid Tumors. The study comprised of:&#xD;
&#xD;
      Escalated cohorts A-H: 27 male or female participants, ages 18-80, BMI 18-36 diagnosed with&#xD;
      inoperable, recurrent or metastatic malignant solid tumors, deemed incurable, and who have&#xD;
      failed to respond to standard therapy or for whom no standard therapy is available. Eligible&#xD;
      subjects will be assigned, successively in order of accrual, to one of eight cohorts, to&#xD;
      receive escalating doses of intravenously infused PROMITIL. PROMITIL will be administered as&#xD;
      an intravenous infusion. Dose escalation will only proceed in the absence of dose-limiting&#xD;
      toxicity (DLT). For this purpose, each cohort will only begin its first cycle of PROMITIL&#xD;
      when the cohort preceding it has successfully completed its first 4-week cycle without any&#xD;
      signs of DLT.&#xD;
&#xD;
      Expanded cohort: 17 adult patients with metastatic CRC. The purpose of this expanded cohort&#xD;
      is to further evaluate the safety of Promitil and to search for signs of antitumor activity&#xD;
      of Promitil in this specific patient population.&#xD;
&#xD;
      Combination Cohort (Promitil concomitantly with Capecitabine): 23 adult patients with&#xD;
      metastatic CRC.&#xD;
&#xD;
      Triple combination Cohort: 13 additional subjects with metastatic CRC, received combination&#xD;
      of Promitil concomitantly with Bevacizumab (5 mg/kg) on day 1 of a 28 day cycle and&#xD;
      Capecitabine on days 1-14 of a 28 day cycle.&#xD;
&#xD;
      3 weekly cohort- 9 subjects with metastatic CRC will receive Promitil and Bevacizumab (7.5&#xD;
      mg/kg) on day 1 of a 21 day cycle.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For all cohorts, PROMITIL will be administered as an intravenous infusion at an initial rate&#xD;
      of 0.25mg/min followed by gradual increase to a maximal rate of 2mg/min until completion of&#xD;
      dosing, if absence of infusion reactions is established and in line with most updated version&#xD;
      of IFU available for this study.&#xD;
&#xD;
      For each subject, subsequent dosing will take place 28 days after the previous treatment,&#xD;
      provided they are deemed fit to be dosed again.&#xD;
&#xD;
      Patients will return to the study center on days 8, 15, 22 of cycle 1, and on day 15 of&#xD;
      cycles 2 and 3, for monitoring assessments.&#xD;
&#xD;
      All patients will be followed-up for survival and post-Promitil treatment. Patients who did&#xD;
      not received 3 cycles of PROMITIL will be followed up only until PD.&#xD;
&#xD;
      For the 3 weekly cohort Promitil will be administered at 3 week interval together with&#xD;
      Bevacizumab (7.5 mg/kg). Patients will return to the study center on days 8 and 15 of cycle&#xD;
      1, and on day 15 of cycles 2 and 3, for monitoring assessments.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">June 2018</completion_date>
  <primary_completion_date type="Actual">November 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximal Tolerated Dose (MTD) of PROMITIL</measure>
    <time_frame>First cycle of treatment (4 weeks)</time_frame>
    <description>Only DLTs occurring during the first cycle of treatment for each participant will determine MTD endpoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Limiting Toxicity (DLT) of PROMITIL</measure>
    <time_frame>First cycle of treatment (4 weeks)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) profile of PROMITIL</measure>
    <time_frame>3 cycles of treatment (12 weeks)</time_frame>
    <description>PK assessments will monitor plasma levels of MLP and metabolite (MMC), as well as PK parameters (Cmax, AUC0-t, AUC 0-∞, MRT, t½ , Kel, Cl, VD).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-tumor responses to the delivered PROMITIL regimens</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity profile of PROMITIL</measure>
    <time_frame>3 cycles of treatment (12 weeks)</time_frame>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Cancer</condition>
  <condition>Solid Tumor</condition>
  <condition>Metastatic Colorectal Cancer (mCRC)</condition>
  <arm_group>
    <arm_group_label>Cohort A: Promitil 0.5 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three treatment cycles, intravenous infusion of Promitil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B: Promitil 1.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three treatment cycles, intravenous infusion of Promitil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C: Promitil 1.5 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three treatment cycles, intravenous infusion of Promitil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort D: Promitil 2.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three treatment cycles, intravenous infusion of Promitil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort E: Promitil 2.5 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three treatment cycles, intravenous infusion of Promitil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort F: Promitil 3.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three treatment cycles, intravenous infusion of Promitil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort G: Promitil 3.5 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three treatment cycles, intravenous infusion of Promitil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort H: Promitil 4.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three treatment cycles, intravenous infusion of Promitil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expanded Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients treated with the selected RP2D of PROMITIL (3 mg/kg) intravenously administered on their first cycle and reduced dose of 2 mg/kg from cycle 2 and onwards.&#xD;
Only for mCRC patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients treated with one cycle of 2.5mg/kg Promitil day 1 together with Capecitabine 1,000 mg bid po days 1-21 followed by two cycles of 2.0 mg/kg Promitil day 1 together with Capecitabine 1,000 mg bid po days 1-21, at four-week intervals.&#xD;
Only for mCRC patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Triple combination Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients treated with one cycle of 2mg/kg Promitil I.v and 5 mg/kg Bevacizumab i.v on day 1 together with Capecitabine 1,000 mg bid p.o days 1-14 at four-week intervals.&#xD;
Only for mCRC patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 Weekly Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients treated with one cycle of 2mg/kg Promitil I.v and 7.5 mg/kg Bevacizumab i.v on day 1 together at three-week intervals.&#xD;
Only for mCRC patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Promitil</intervention_name>
    <description>2 mg/kg dose IV</description>
    <arm_group_label>3 Weekly Cohort</arm_group_label>
    <arm_group_label>Cohort A: Promitil 0.5 mg/kg</arm_group_label>
    <arm_group_label>Cohort B: Promitil 1.0 mg/kg</arm_group_label>
    <arm_group_label>Cohort C: Promitil 1.5 mg/kg</arm_group_label>
    <arm_group_label>Cohort D: Promitil 2.0 mg/kg</arm_group_label>
    <arm_group_label>Cohort E: Promitil 2.5 mg/kg</arm_group_label>
    <arm_group_label>Cohort F: Promitil 3.0 mg/kg</arm_group_label>
    <arm_group_label>Cohort G: Promitil 3.5 mg/kg</arm_group_label>
    <arm_group_label>Cohort H: Promitil 4.0 mg/kg</arm_group_label>
    <arm_group_label>Combination Cohort</arm_group_label>
    <arm_group_label>Expanded Cohort</arm_group_label>
    <arm_group_label>Triple combination Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>1000 mg dose BID PO for days 1-21 for Combination Cohort and on day 1-14 on Triple combination Cohort</description>
    <arm_group_label>Combination Cohort</arm_group_label>
    <arm_group_label>Triple combination Cohort</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>for Triple combination cohort an IV dose of 5 mg/kg on day 1 at 4 week interval. For the 3 weekly cohort an IV dose of 7.5 mg/kg at 3 week interval.</description>
    <arm_group_label>3 Weekly Cohort</arm_group_label>
    <arm_group_label>Triple combination Cohort</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients diagnosed with inoperable, recurrent or metastatic malignant solid tumors,&#xD;
             deemed incurable, and who have either:&#xD;
&#xD;
               -  Failed to respond to standard therapy or&#xD;
&#xD;
               -  For whom no standard therapy is available or&#xD;
&#xD;
               -  Refuse to receive standard therapies&#xD;
&#xD;
          2. Histologically or cytologically confirmed diagnosis of solid tumor on file.&#xD;
&#xD;
          3. Age 18-80 years&#xD;
&#xD;
          4. BMI: 18-36&#xD;
&#xD;
          5. ECOG Performance Status ≤ 2&#xD;
&#xD;
          6. Estimated life expectancy of at least 3 months&#xD;
&#xD;
          7. Adequate bone marrow function (an absolute neutrophil count ≥1500/mm3, hemoglobin ≥9.5&#xD;
             g/dl, HgbA1C≤7%, and a platelet count ≥100,000/mm3(&#xD;
&#xD;
          8. Adequate liver function (serum bilirubin ≤2.0 mg/100 ml; alanine aminotransferase ≤2×&#xD;
             ULN)&#xD;
&#xD;
          9. Adequate renal function (serum creatinine ≤1.5 mg/100 ml or creatinine clearance ≥45&#xD;
             ml/min/1.73m2)&#xD;
&#xD;
         10. No prior intravenous treatment with Mitomycin-C either alone or in combination&#xD;
&#xD;
         11. No other myelosuppressive treatment within 4 weeks before start of the study drug.&#xD;
&#xD;
         12. No other anti-cancer treatment within 2 weeks before start of the study drug&#xD;
&#xD;
         13. No prior extensive radiotherapy (e.g., whole pelvis total neuroaxis or greater than&#xD;
             50% of neuroaxis, whole abdomen, whole body or half-body) or bone marrow&#xD;
             transplantation with high dose chemotherapy and/or total body irradiation.&#xD;
             Re-irradiation of a field in abdomen/pelvis will be considered as extensive&#xD;
             radiotherapy, excluding such patients from the study.&#xD;
&#xD;
         14. Women of child bearing potential practicing an acceptable method of birth control.&#xD;
&#xD;
         15. Understanding of study procedures and willingness to comply for the entire length of&#xD;
             the study and to give written informed consent.&#xD;
&#xD;
         16. Additional criteria only for the Expanded Cohort and both Combination cohorts:&#xD;
             Patients with histologically or cytologically confirmed recurrent and/or metastatic&#xD;
             measurable or nonmeasurable CRC, with tissue or cytological diagnosis of cancer on&#xD;
             file.&#xD;
&#xD;
         17. Additional criteria only for the Expanded Cohort and both Combination cohort: Patients&#xD;
             who demonstrated either progression or intolerance when treated with irinotecan and&#xD;
             fluopyrimidine-based chemotherapy, and, in the case of K-ras wild type tumors,&#xD;
             anti-EGFR antibodies (Cetuximab, Panitumumab). Prior treatment with oxaliplatin or&#xD;
             bevacizumab is allowed but not required.&#xD;
&#xD;
         18. Additional criteria only for the Expanded Cohort and both Combination cohorts: A ≥28&#xD;
             day treatment-free interval between last chemotherapeutic treatment and first&#xD;
             treatment with Promitil, with the exception of Capecitabine and biological therapies,&#xD;
             where 14-day treatment-free intervals suffice. this is also relevant for patients in&#xD;
             the Combination Cohort that are currently taking Capecitabine prior to enter the&#xD;
             study).&#xD;
&#xD;
         19. Additional criteria for the Triple Combination Cohort with bevacizumab only: Prior&#xD;
             exposure to oxaliplatin should have terminated at least 6 months before start of&#xD;
             PROMITIL, whether given as adjuvant therapy or as therapy for metastatic disease.&#xD;
&#xD;
         20. Additional criteria for the triple Combination Cohort with bevacizumab only: A ≥ 28&#xD;
             day treatment-free interval from last bevacizumab treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known hypersensitivity to the study drug or to any of its components&#xD;
&#xD;
          2. CHF (NYHA = Class IV) or LVEF≤40%&#xD;
&#xD;
          3. COPD &gt; Stage 3 (FEV1&lt;50%, FEV1/FVC&lt;70%);&#xD;
&#xD;
          4. Cirrhosis (Child-Pugh Class C score);&#xD;
&#xD;
          5. Serum Albumin level &lt; 3 g/dl&#xD;
&#xD;
          6. Any other severe concurrent disease which in the judgment of the investigator would&#xD;
             make the subject inappropriate for entry into this study&#xD;
&#xD;
          7. History of human immunodeficiency virus (HIV) infection&#xD;
&#xD;
          8. History of chronic active hepatitis including subjects who are carriers of hepatitis B&#xD;
             virus (HBV) or hepatitis C virus (HCV).&#xD;
&#xD;
          9. Presence of uncontrolled infection.&#xD;
&#xD;
         10. Evidence of active bleeding or bleeding diathesis&#xD;
&#xD;
         11. Brain metastases in symptomatic patients requiring ≥4 mg dexamethasone/day. However,&#xD;
             patients with treated brain metastases by surgery or radiation who are stable and&#xD;
             symptom-free (&lt;4 mg dexamethasone/day) for a minimum period of 4 weeks post-treatment&#xD;
             are eligible.&#xD;
&#xD;
         12. Pregnant or lactating&#xD;
&#xD;
         13. Treatment with other investigational drugs within 14 days of start of the study drug&#xD;
             for non-myelosuppressive agents, and within 28 days of start of the study drug for&#xD;
             myelosuppressive agents.&#xD;
&#xD;
         14. Additional criteria for the Combination cohorts: Uncontrolled ascites (defined as 2 or&#xD;
             more palliative taps in the last 30 days before screening).&#xD;
&#xD;
         15. Additional criteria for the Combination cohorts with bevacizumab only: uncontrolled&#xD;
             clinically significant cardiac disease, hypertension, arrhythmias, or angina pectoris;&#xD;
             acute myocardial infarction or cerebrovascular accident within 12 months of initiation&#xD;
             of PROMITIL treatment.&#xD;
&#xD;
         16. Additional criteria for the Combination cohorts with bevacizumab only: Any&#xD;
             contraindication for treatment with Bevacizumab (e.g active bleeding, recent extensive&#xD;
             surgery).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Rambam Health Care Campus</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shaare Zedek Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chaim Sheba Medical center</name>
      <address>
        <city>Ramat Gan</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tel-Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel-Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>October 8, 2012</study_first_submitted>
  <study_first_submitted_qc>October 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2012</study_first_posted>
  <last_update_submitted>July 9, 2018</last_update_submitted>
  <last_update_submitted_qc>July 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>phase 1</keyword>
  <keyword>dose escalating</keyword>
  <keyword>prodrug</keyword>
  <keyword>mitomycin C</keyword>
  <keyword>Capecitabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

